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There is evidence that commercial formalinized poliomyelitis vaccine pro- 
duces a  significant degree of protection in those vaccinated against the para- 
lytic form of the disease. However, a  number of questions remain to he an- 
swered, such as: first, the duration of immunity produced by a killed vaccine, 
and the necessity and frequency of revaccination; secondly, the fundamental 
questions about the quality of the immune state resulting from such vaccina- 
tion as compared with that resulting from natural, inapparent infection. There 
are indications of qualitative differences in the two types of immunity (natural 
and artificial)  from  the  observations  of  Lipson,  Robbins,  and  Woods  (1), 
Gelfand and coworkers (2), and Davis and Melnick (3), that vaccinated associ- 
ates of frank cases of poliomyelitis when exposed become infected and excrete 
virus in  the feces as readily as do non-vaccinated contacts under similar cir- 
cumstances. The results to date suggest that although formalinized vaccine pro- 
duces antibodies and protects against the paralytic disease, it does not protect 
against the infection of the intestinal tract, possibly because the oropharynx 
and intestinal tract, never having been exposed, have not been "immunized." 
The fact that a  recently vaccinated individual, largely protected against the 
paralytic disease, subsequently becomes infected without harm when exposed 
to virus might be interpreted as a  desirable situation in that, by such means, 
he acquires a  natural boost to his immunity. He has then the advantages of 
some immunity against paralysis provided by the vaccine, and on his own, he 
acquires an alimentary infection which is believed to be associated with durable 
immunity. 
If this theory is correct,  the question  arises as to whether the acquisition  of ali- 
mentary infection and its desirable results  in terms of lasting immunity should be 
left to chance; or whether,  following vaccination  with the formalinized preparation 
and the production of antibodies by this means, it might not be possible to follow with 
oral vaccination,  employing the living, attenuated strains of poliovirus such as have 
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been developed recently. Ideally, this would eliminate chance in the production of 
complete and  lasting immunity,  an  important  consideration, since the  amount  of 
natural exposure likely to occur varies so markedly in different populations with dif- 
ferent ways of life, and in some groups chance, in this respect, would be likely  to prove 
undependable indeed. This aspect has been discussed in a recent paper (4) by one of 
US. 
The present report is concerned with observations on a  small group whose anti- 
bodies had been acquired naturally, or in one instance by vaccination, in which oral 
immunization against poliomyelitis with  a  live attenuated  strain of poliovirus was 
tried. The first of such trials with live poliovirus was carried out in 1950  by Koprow- 
ski, Jervis, and Norton,  who fed a  rodent-adapted Type II strain of poliovirus to 
volunteers who  were  without  Type II antibodies, and  followed their  excretion of 
virus and development of neutralizing antibodies (5). These workers have also induced 
infection and  immune responses in similar trials with a  rodent-adapted attenuated 
Type I strain (6); in addition both strains have been fed by Koprowski eta/. to infants 
possessing passive antibody acquired from their mothers (27), and by Dane and Dick 
to infants, children and adults (30). Attenuated strains of all three types of virus have 
been developed by manipulating strains in tissue culture (7-10), and examples of each 
type have been fed to humans by Sabin (11-14). It is apparent from the work of both 
Koprowski and Sabin, that infection is readily induced in humans who do not possess 
antibodies to poliovirnses, using doses as small as 0.001  nil., containing approximately 
10,000  tissue culture doses of virus (12). Virus has also been fed by these workers to 
individuals with  naturally  acquired  antibodies,  some  of  whom  became  reinfected 
(5,  12-14).  None of the laboratory attenuated strains fed have induced illness and 
with the exception of  one instance (30)  none has been found  to  produce viremia in 
infected individuals in the course of the induced inapparent infection. 
In our trial, an attenuated Type III strain of poliovirus was fed to individuals who 
already possessed Type IH  antibodies, either  as  a  result  of natural  infection,  or 
following vaccination with commercial formalinized Salk vaccine. Our purpose was to 
determine the ease of infection--or reinfection--in these two types of individuals to 
see whether a qualitative difference in immunity could be detected; and to determine 
whether  in addition to neutralizing antibody responses, reinfection is accompanied 
by the appearance of complement-fixing antibodies. We were also concerned with the 
question as to whether infection would spread to those contacts in close association 
with the individuals receiving the attenuated poliovirus. 
Materials and Methods 
The trial was carried out beginning in January, 1956, on the female tuberculosis  ward of 
an institution caring for feeble minded children and adults,  t The unit selected was a  15 bed 
isolation ward consisting of 2 rooms, one with 10 beds, and one with 5. Gown and mask iso- 
lation technique  was practiced, and all dishes were sterilized on the floor. During the trial 
all bed linen was sterilized in the basement in a steam sterilizer. 
The local staff concerned with patient care consisted of two registered nurses, and a num- 
ber of trained attendants.  These  individuals worked  only on  the  tuberculosis  ward,  and 
1 We are greatly indebted to Dr. (]rover F. Powers  and Dr. Herman Yannet for their 
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were never transferred to other parts of the institution. A  "dean" room was provided for 
them where outer clothing was changed. Members of the local staff received formalinized 
vaccine 1 month before the trial was begun. 
Subjects.--The entire ward  housed  13  patients, all of whom  took part  in the  trial.  All 
but two were ambulatory, and spent most of the day out of bed visiting, and taking  their 
meals in a  small dining room. Several of the ambulatory patients were fed at their bedsides 
for administrative reasons. 
The bowel habits of the ambulatory patients were good within the limits of their intel- 
ligence. Extra attention to this problem was given to the individuals of low grade intelligence. 
One of the two bed patients was incontinent. 
TABLE  I 
Tested and Control Subjects, Type III Poliovirus Feeding Trial 
;roup A  (tested) 
}roup B  (con- 
trois---exposed) 
No.  I 
S-21 
S-9 
S-8 
S-17 
S-40" 
S-4 
S-18 
S-22 
S-29 
S-31 
S-36 
S-382 
S-1 
Age 
47 
45 
39 
52 
9 
53 
26 
36 
52 
32 
47 
44 
51 
Virus dose 
TCDi0 
107.5 
104.5 
None 
,c 
cl 
cc 
Preexposure neutralizing antibodies 
I  H  HI 
256  0  64 
8  64  8 
64  16  64 
64  64  16 
0  64*  16" 
256  64  256 
64  0  256 
<8  256  256 
64  256  256 
16  16  64 
64  0  256 
16  64  0 
64  64  16 
* Vaccinated  child,  antibody  acquired  after  2  injections  of  formalinized  vaccine. 
The group was  divided into two parts, one: those receiving the attenuated virus, num- 
bering 5; and the other the controls, consisting of associates, 8 in number. The ages of mem- 
bers of both groups ranged from 26 to 53, with one exception, a  girl of 9. The latter was a 
case of tuberculous meningitis inactive, with severe brain damage;  she had been comatose 
and tube fed for 3 years. The other 12 had been diagnosed arrested or inactive tuberculosis. 
Eleven of the  13 patients had Type  III antibodies when their sera were tested  several 
months before the trial was begun. Of the two without such antibodies, one remained as an 
antibody negative control (S-382),  and the other (S-40) received 1 ml. of formalinized vac- 
cine twice,  1 week apart, beginning I  month before virus feeding. 
The ages and antibody status of the vaccine trial and control groups at the beginning of 
the procedure is given in Table I. 
Vir~s.--An attenuated strain of Type III, Leon KP-34, was generously supplied by Dr. 
Albert B.  Sabin,  of  the  Children's Hospital  Research  Foundation,  Cincinnati. This strain 
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1952  (16)  and  subsequently attenuated in  the course  of passage  through monkey kidney 
cultures by Sabin (9). Its attenuation, purity, and loss of capacity to produce paralysis on 
intracerebral inoculation of monkeys have been described  (9,  11,  12).  The  virus pool em- 
ployed in our trial was an aliquot of a  lot which had been tested extensively by Sabin and 
fed by him to 18 volunteers. The titer of the pool was  107.5 TCD60 per ml. when  tested  in 
Sabin's laboratory in April, 1955.  Prior to its use by us, the titer of this virus in tissue cul- 
ture  (monkey kidney cells) was determined in half log dilutions by the tube method, using 
TABLE  II 
Schedule of Specimens for Collection and Testing 
Time 
Group A  Group B 
Vaccine trial  (Control) 
Bloods  Throat swabs  Stools  Bloods 
Prefeeding  5 *  5  5  8 
Posffeeding 
6 hrs.  5 
1 day  5  5 
2 days  5  5 
3  5  5  5 
4  5  5  5 
5  5  5  5 
6  5  5  5 
7  5  5  5  8 
10  5  5  5 
14  5  5  5 
21  5  5  5  8 
28  5  5  5 
35  5  5 
42  5  5  5  7:[: 
63  5  5  7 
84  5  5  7 
totals.  65  75  80  45 
Throat swabs  Stools 
8  8 
8  8 
8  8 
8  8 
8  8 
8  8 
8  8 
8  8 
8  8 
8  8 
8  8 
8  8 
8  8 
7~  75 
7 
7 
111  125 
* The numbers stand for the number of specimens desired from  the five individuals in 
the vaccine trial and the eight members of the control group. 
:~ One control died. 
6 tubes per dilution, and by the plaque method as modified for bottles by Hsinng and Mel- 
nick (17). In tubes, the result was I0  TM TCD~ per ml.; by plaque count  2 it was 10  7.6 plaque- 
forming units (PFU) per ml. 
Virus Feeding Schedule.--Based on Sabin's experience (11,  12)  two dosages of virus were 
used:  3  individuals received  10  +.~ TCD~ of  virus and 2  individuals  received  l&  3 TCD+0. 
The virus was added to 4  to 6 ml. milk and this material was fed in a  tablespoon at 11:00 
a.m., January 10,  1956, several hours after breakfast, and preceding lunch by one-half hour. 
One individual, S-40,  who was comatose,  received the virus by stomach tube; in addition, 
her throat was swabbed with the virus-milk mixture. 
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Collection and Preparation o/Specimens.--Table II shows the schedule set up for the col- 
lection of:  1,  blood specimens for virus testing and for antibody determinations; 2,  throat 
swabs; and 3,  stools, for virus isolation.  Except for minor deviations, the schedule was ad- 
hered to closely. 
Blood specimens were collected in vacuum syringes, allowed to clot, and separated either 
on the day of collection, or on the following morning if blood was drawn late in the after- 
noon. Throat swabs were placed in 1 ml. of sterile saline; both stools mad throat swabs were 
frozen immediately after collection and kept frozen until tested. 
Throat swabs were extracted in a  total of 2 ml. of saline, containing 500/~g. penicillin and 
500 #g. streptomycin. Before inoculation into tissue culture tubes the extracts were spun at 
3000 I~.P.M. for 15 minutes, the sediment being discarded. 
Stool specimens were collected according to the schedule in Table II. They were immedi- 
ately stored in the frozen state and were subsequently prepared and inoculated in the routine 
manner used in this laboratory (18). After thawing, 5 gin. were weighed out, and mixed with 
27 ml. of sterile water, in a pyrex bottle. The suspension was shaken for 1 hour on a mechan- 
ical shaker, then centrifuged at 4000 l~.P.~, for 1 hour. To the supernatant fluid which con- 
stituted the inoculum, 500/~g. of penicillin and 500/~g. of streptomycin per ml. was added. 
Testing of Specimens for Virus.--Culture tubes containing trypsinized monolayer monkey 
kidney tissue grown in a  medium  containing 0.5 per cent ]actalbumin hydrolysate,  2  per 
cent calf  serum,  and 97.5  per cent Hank's salt solution were  used  throughout.  Sera were 
inoculated in 0.1 ml. amounts, into 10 tubes per specimen; mad throat swabs, 0.2 ml. into 3 
tubes per specimen. Tubes to be inoculated with stool specimens were drained of media, and 
1 ml. of the clarified stool suspension was added; after 1 hour's incubation at room tempera- 
ture the inoculum was removed from the culture tubes and replaced with 1 ml. of media. Six 
tubes were used per specimen. 
All tubes were observed for 12 days; those showing degeneration were harvested mad passed. 
If, after 12 days, the kidney tissue appeared normal, a  blind passage was made to 4  tubes, 
which in turn were observed for 12 days. 
All isolates were identified in neutralization tests set up against the 3 types of poliovirus 
as well as a pool of the 3 types (18). Each positive specimen was titrated in log dilutions and 
the TCso per ml. of throat swabs, and per gram of stool, were calculated by the Reed-Muench 
formula. 
Monkey  Virulence Tests on  Virus  Excreted by Infected Subjeas.--Virus  strains isolated 
from two individuals were tested for their ability to produce paralysis in monkeys on intra- 
cerebral or intraspinal injection, to determine whether human passage had altered the neu- 
rotropism of the strain fed.  Virus from the last positive stool was selected for this kind of 
test in each instance. This represented in the ease of subject S-9,  the stool collected on day 
13, which had a  titer of 10  x~ per gram, and for subject S-40,  the stool collected on day 41, 
titering 10  *.° per gin. The two isolates were given a  second tissue culture passage, and the 
harvest was titered in tissue culture in the usual manner described above. At the same time 
log dilutions were inoculated intracerebrally or intraspinally into three monkeys per dilution. 
Both rkesus (Maraca mulatta)  and cynomologus (Maraca cynomolgus) monkeys were used. 
The animals were followed for 4  weeks and sacrificed at that time,  or earlier, if paralysis 
occurred.  Histological sections from  the  CNS  of all animals were  examined for lesions of 
poliomyelitis. 
Serological Tests.--Sera  were inactivated at 56°C. for 30 minutes prior to testing for anti- 
bodies. Serial specimens from each individual were run in the same test. 
Neutralization tests were carried out by the pH colorimetric method as modified by Mel- 
nick and Opton (19), using disposable plastic panels, and versenized second passage monkey 
kidney cells.  Sera were tested in a  preliminary screening at 1:4,  1:8,  1:16,  1:64,  1:256, and 164  ORAL ADMINISTRATION  OF  ATTENUATED POLIOVIRUS 
1:1024, using 1 cup per dilution. Most specimens from those individuals who became in- 
fected were subsequently titrated  over a wider range of 2-fold dilutions, using 3 cups per 
dilution. 
Complement fixation tests (designated hereafter as CF) were set up on plastic plates, using 
the method of Fulton and Dumbell (20) as modified by Black and Melnick (21). Tissue cul- 
ture-gown antigens of the three types of poliovirus were used; in some tests both unheated 
and heated (56  ° for 30 minutes) antigens were used, but since there were no differences de- 
tected between the two with the antigens then in use, only  heated preparations were used in 
the later tests. 
RESULTS 
Four of  the  five  individuals  fed  virus  developed  inapparent  infection,  as 
evidenced by virus  excretion  and  antibody  responses.  The  results  for  each 
individual including the amounts of virus excreted are given in detail  in the 
accompanying tables,  III to VII. At no time did any of the infected subjects 
or controls have any symptoms or signs of illness  suggestive of poliomyelitis. 
None showed any significant temperature rises. 
None of the control subjects who were living in the same ward and thus were 
exposed  to  those  with  inapparent  infection  became  infected.  Their  throat 
swabs  and  stools  were  repeatedly  negative  for virus  and  none  showed any 
antibody shift. The one control without Type III antibodies  (S-382)  did not 
acquire them. Another control ($-1) died from a  malignant neoplasm 41 days 
after the experiment was begun. 
L  Results with the Smaller Dose  of  Virus  (104.STCDso).--There  were  three 
individuals  in  this  group,  two  with  natural  antibodies,  and  one  with  Type 
III antibodies induced by vaccination. Of the two with natural antibodies,  one 
became infected,  No.  S-8  (Table  III). The prefeeding Type III neutralizing 
antibody titer of this individual was 1:64. Virus was not detected in her throat, 
but was present in the stools from the 2nd through the 7th day. She showed a 
rise  in  neutralizing  antibodies  to  Type III on the  10th  day; CF  antibodies 
rose on the 14th day, both to Types II and III. 
The second individual, No. S-17  (Table IV), failed to become infected. Her 
Type III neutralizing antibody titer was  16 before feeding, and remained at 
that level.  No CF antibodies appeared. 
The one individual who acquired Type III antibodies as a result of vaccination 
with forraalini~.ed vaccine  (S-40)  became  infected  after  feeding  and  excreted 
virus in the stool from the 3rd through the 41st day; the next stool tested was 
excreted on day 63, and was negative (Table V). Virus was not recovered from 
the  troat  or blood of this  individual.  Neutralizing antibodies  8 against Types 
II and  III rose between  the  10th  and  21st  day.  CF antibodies  to all  three 
types appeared on day 10. 
*  Prior to receiving formalinized vaccine the neutralizing antibody pattern on this child 
was 0, < 8, < 4, for the 3 types; on the day of feeding (1 month after vaccination) it was 0, 
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TABLE  III 
Virus Excretion and Antibody Response in Patient S-8, Type III  Virus Small Dose 
(104"6 TCD~o) Fed on January 10, 1956 
Virus isolation*  Antibodies 
Time of  Neutralization  CF titer  CF avidity 
specimen  Blood Throat Stool 
Prefeeding  0  0 
Postfeeding 
6 hrs.  0 
1 day  0  0 
2 days  0  3.3 
3  0  0  3.9 
4  0  0  4.6 
5  0  0  3.4 
6  0  0  3.4 
7  0  0  3.4 
10  0  0 
13  0 
14  0 
16  0 
17  0 
2O 
21  0 
24  0 
27  0 
28  0 
34  0 
35  0 
40  0 
41  0 
63 
72 
83 
84 
I  II  III  I 
64  16  64  8 
I  II  III 
9  17  11 
64  64  256  8 
64  256  1,024+  8 
64  256  16,000+  16 
64  256  1,024+  16 
64  256  16,000+  16 
256  256  1,024+  8 
256  64  1,024+  8 
128  64  16,000+  4  8 
II  III 
16  8 
16  8 
16  16 
32  32 
32  32 
32  32 
16  16 
8  16 
9  17+  I0+ 
13  20  22+ 
18  33+  35+ 
17  31+  35+ 
20+  33+  31-[- 
18+  25+  28~ 
14+  15+  20-~ 
* In this Table, and in Tables  V to VII isolation from throat swabs is expressed as log 
TCD~0 per hal., and isolation from stools is expressed as log TCD~0 per gin. 
II.  Results  with the Larger  Dose  of  Virus  (107.STCD~o).--Both  individuals 
who were fed the larger dose became infected; both excreted virus in the throat 
and in the feces. 
No.  S-21  (see  Table VI)  whose  prefeeding Type  III  titer  was  1:64  had 
virus in the throat from the 4th through the 6th day, and in the stool from the 
1st  through  the  7th  day.  Type III neutralizing antibodies rose  on the  10th 
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TABLE IV 
Virus and Antibody Tests on Patient S-17,  Type III  Virus  (10  *.5 TCD6o) Fed on January 
10, 1956 
Virus isolation  Antibodies 
Time of specimen  Neutralization  CF titer  CF avidity 
Blood  Throat I Stool 
?refeeding 
Postfeeding 
6 hrs. 
1 day 
2 days 
3 
4 
5 
6 
7 
8 
10 
13 
14 
16 
17 
2O 
21 
24 
27 
28 
34 
35 
40 
41 
42 
62 
63 
72 
83 
84 
105 
0  0 
0  0 
0  0 
0  0 
0  0 
0  0 
0  0 
0  0 
0  0 
0  0 
0  0 
0  0 
0 
0 
0 
0  0 
0 
0 
0 
0 
I  II  HI  I  II 
64  64  16  0  0 
256  64  16  0  0 
64  64  16  0  0 
64  64  16  0  0 
64  64  16  0  0 
64  32  16  0  0 
64  64  16  0  0 
64  64  16  0  0 
III  I  II  III 
0  0  0  0 
0  0  0  0 
0  0  0  0 
0  0  0  0 
0  0  0  0 
0  0  0  0 
0  0  0  0 
0  0  0  0 
day; an heterotypic rise to Type II appeared at the same time but had faded 
away by day 63. The CF response was minimal, rising on the 14th day, and 
falling to insignificant levels by the 28th day. 
No.  S-9 (see Table VII), whose prefeeding Type III antibody level was 8, 
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TABLE V 
Virus  Excretion and Antibody Response in  Patient S-40, Type  III  Virus Small Dose 
(104.~TCDso) Fed on January 10, 19~6 
Time of Specimen 
Prevaccination* 
Prefeeding 
Postfeeding 
6 hrs. 
1 day 
2 days 
3 
4 
5 
6 
7 
8 
10 
13 
14 
17 
2O 
21 
24 
27 
28 
29 
35 
41 
60 
63 
70 
76 
83 
84 
Virus isolation  Antibodies 
Blood  Throat  Stool  - 
..._I_I. 
0 
0  0 
0  0 
0 
0  0 
0  0  3.6 
0  0  2.4 
0  0  3.1 
0  0  4.6 
0  0  4 
4.1 
0  4.4  4 
2.5 
8 
0  3.6 
2.4 
0 
2.4 
0  4 
0  2.5 
0  3.0  4 
Neutralization  CF titer  CF avidity 
II  III  I  II  III  I  II  HI 
<8  <4  0  0  0  0  0  0 
64  16  8  0  0  8  0  0 
64  16  8  4  4  14  2  4 
256  64  32  32  32  38+  39+  31+ 
256  256  32  32  32  39+  40+  31-I- 
32  32  16  35+  33+  27+ 
1000+  256  32  16  16  33+  26+  20-{- 
1000+  256  16  8  8  25+  19  17+ 
4  64 
8  128 
64  16  8  8  21+  12  12 
64  4  0  0  6  0  0 
* This child received  1 ml. of formalinized  vaccine  on  December  6 and again  on  De- 
cember  13. 
stool from the 4th  through  the  13th day.  Neutralizing antibodies to all three 
types rose sharply on the  10th day, and were still high on the 63rd day. The 
CF response was insignificant: a  titer of 1 "4 (with an avidity of 6)  was pres- 
ent on the 14th and 21st days, and then disappeared. 
III.  Monkey  Virulence  Tests  on  Type  III  Strain  Isolated from  Stools.-- 168  OP~L  ADMINISTRATION OF  ATTENUATED POLIOVIRUS 
Virus derived from the last positive stool specimen of volunteers S-9 and S-40, 
collected  13  and 41  days respectively after feeding, were tested for paralyto- 
TABLE VI 
Virus Excretion  and Antibody  Response in Patient S-21,  Type III  Virus  Large Dose 
(10  r'6 TCDso) Fed on January 10, 1956 
Virus isolation  Antibodies 
Time of specimen  Neutralization  I  CF titer  CF avidity 
Blood  I 
Prefeeding 
Postfeedlng 
6 hrs. 
1 day 
2 days 
3 
4 
5 
6 
7 
10 
13 
14 
16 
17 
2O 
21 
24 
27 
28 
35 
40 
41 
62 
63 
83 
84 
Throat  Stool 
0  0 
0 
0 
0 
0 
1.4 
<0.5 
<0.5 
0 
0 
3.4 
4.0 
3.6 
2.9 
3.0 
3.0 
3.6 
0 
0 
I  II  III 
256  0  64 
256  0  64 
256  16  1000+ 
128  8  8000 
256  16  1000+ 
256  8  1000 
I  II  III  I  II  IIl 
000000 
000000 
000000 
0080018+ 
0080015+ 
004004 
256  8  1000  0  0  0  0  0  0 
256  8  1000  0  0  0  0  0  0 
128  4  1000  0  0  0  0  0  0 
genic capacity by inoculation of rhesus and cynomolgus monkeys intracerebrally 
or intraspinally. Tests on the attenuated KP34 strain of Type III which was 
fed to these individuals had previously been carried  out  by  Sabin et al.  (9), 
who reported that the virus failed to produce paralysis in cynomolgus monkeys 
on intracerebral injection, even when  107.2TCD~0 were given; he found that HORSTMANN, PAUL~ 1KELNICK~ AND  DEUTSCH  169 
none  of  28  monkeys  receiving  intracerebral  dosages  ranging  from  101.2 to 
107.2TCDs0  (4 animals per dilution) developed paralysis or demonstrable CNS 
lesions. Subsequently, Sabin found on further tests with the KP34 strain that 
a  certain proportion of monkeys inoculated intracerebrally with large amounts 
TABLE VII 
Virus  Excretion  and  Antibody  Response in Patient  S-9,  Type III  Virus Large Dose 
(107.6 TCD6o) Fed on January 10, 1956 
Virus isolation  Antibodies 
Time of specimen  Neutralization  CF titer  CF avidity 
Blood  Throat 
Prefeeding  0 
?ostfeeding 
6 hrs.  0 
1 day  0 
2 days  1.0 
3  0  1.2 
4  0  .5 
5  0  1.2 
6  0  2.2 
7  0  0 
10  0 
13 
14  0 
17  0 
20 
21 
24 
27 
28 
35 
41 
63 
84 
Stool 
I  II  III 
0  8  64  8 
I  II  III  I  [II  III 
000000 
0 
0 
0 
2.9 
3.2 
1.8 
1.8 
16  256  64  0  0  0  0  0  0 
1000+  1000+  1000+  0  0  0  0  0  0 
1000+  2000  1000+  0  0  4  0  0  6 
1000+  1000+  I000+  0  0  4  0  0  6 
1000+  2000  1000+  0  0  0  0  0  0 
1000+  1000+  1000+  0  0  0  0  0  0 
1000+  1000+  1000+  0  0  0  0  0  0 
256  1000  256  0  0  0  0  0  0 
of virus developed paralysis (31).  The results when  similar tests were carried 
out with virus excreted by the  two subjects in our trial are shown in Tables 
VIII and IX,  and in Table X,  these are compared with  Sabin's tests on the 
virus fed. In testing the strains isolated from the stools, second tissue culture 
passage was inoculated into monkeys. In each instance,  the TCDs0  was  10  ~.5 
per ml. In the case of virus isolated from volunteer  S-9  (Table VIII), one of 
2  animals  receiving  105.3TCDs0  intracerebrally  developed  paralysis.  Of  the 170  ORAL ADMINISTRATION O]~  ATTENUATED POLIOVIRUS 
TABLE VIII 
Tests for  Virulence on Second Tissue Culture Passage of Stools of Patient S-9, Excreted 13 
Days after Virus Feeding 
Route of 
inoculation 
[ntracere- 
bral 
[ntra- 
spinal 
TC fluid 
concentrstion* 
I0  o 
(10  T.: TCDso) 
10-I 
(106.5  TCDso) 
10-~ 
(105.8  TCD~o) 
10-  5 
(10  'a TCDso) 
10--2 
(10  4.5 TCD6o) 
10-: 
(I08"5  TCD~o) 
10-~ 
(I0  ~'5  TCDso) 
10-5 
(101.5 TCDso) 
Animal No. 
l~t 86-37 
Cy 86-57 
Cy 86-58 
F,h 86-36 
Cy 86-55 
Cy 86-56 
Kh 86-35 
Cy 86-53 
Cy 86-54 
Rh 86-34 
Cy 86-51 
Cy 86-52 
Rh 86-33 
Cy 85-49 
Cy 86-50 
R.h 86-32 
Cy 8647 
Cy 86-48 
Rh 86-31 
CY 8645 
Cy 86-46 
Rh 86-30 
Cy 86-43 
Cy 86-44 
Results 
Paralysis  Pathology 
Inc.~:  N.D. 
-  + 
-  (Inc.)  -  (inc.) 
-  + 
+  + 
-(Inc.)  -(Inc.) 
+  + 
-- (Inc.)  -- (Inc.) 
+  + 
-  + 
-  (Inc.)  -  (Inc.) 
-  (Inc.)  -  (Inc.) 
m 
-  + 
+  + 
-  + 
I 
Comment 
Died, day 1 after 
inoculation 
Typical lesions, lum- 
bar and cervical 
cord 
Died day 14 
Died day 8 
Died day 9 
Lesions cervical and 
lumbar cord 
Died day 5 
Died day 11 
Lesions cervical and 
lumbar cord 
Lesions lumbar cord 
only 
* The titer of the TC fluid was 10  ~.5 per ml. Monkeys were inoculated with 0.6 ml. intra- 
cerebrally, or 0.1 ml. intraspinally.  (TCDs0), dose of virus inoculated. 
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TABLE IX 
Teata for Virulence on Second Tissue Culture Passage of Stools of Patient  S-40,  Excreted 41 
Days after Virus Feeding 
Route  of 
Inoculation 
Iutracere- 
bral 
Intra- 
spinal 
TC Fluid 
Conc.* 
10  0 
(10  ~'s TCD6o) 
10-1 
(10  s.s TCD6o) 
10-~ 
(10  s.* TCDso) 
•  10  -s 
(10  I.s TCDso) 
10"-2 
(104"s TCD+o) 
10-s 
(108-~ TCD60) 
10-~ 
(10  ~.~ TCD~o) 
10-5 
(10  t.~ TCD~o) 
Animal 
Number 
Rh 85-74 
Cy 85-98 
Cy 85-99 
Rh 85-75 
Cy 86-00 
Cy 86-01 
Rh 85-76 
Cy 86-04 
Cy 86-O5 
Rh 85-77 
Cy 86-02 
Cy 86-03 
Rh 85-71 
Cy 85-86 
Cy 86-87 
R.h 85-72 
Cy 85-88 
Cy 85-89 
R.h 85-73 
Cy 85-90 
Cy 85-91 
Cy 85-95 
Cy 85-96 
Cy 85-97 
Results 
Paralysis  Pathology 
--  + 
+  + 
-(Inc.)~t  -(Inc.) 
+  ÷ 
Inc.  N.D. 
+  + 
--  + 
+ 
+  + 
+  + 
-  + 
-  (Inc.)  -  (inc.) 
Comment 
Lesions cervical and 
lumbar cord 
Died day 10 
Died day 2 
Lesions cervical, 
thoracic, and lum- 
bar cord 
traumatic lesion only 
at site of inocula- 
tion 
Mild lesions, at lum- 
bar inoculation anc 
contralateral side 
Died day 15 
Giant ceils at inocu- 
lation site 
* The titer of the TC fluid was i0  ~-5 per ml. Monkeys were inoculated with 0.6 ml. intra- 
cerebrally, or 0.1 ml. intraspinally. (TCDso), dose of virus inoculated. 
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intraspinally inoculated animals receiving the same material, one of 3  inocu- 
lated  with  102.STCD60 developed paralysis,  and  another had  lesions  in  the 
lumbar  cord without  CNS  signs. 
Similar results were obtained with virus derived from the stools of subject 
S-40 (Table IX). One of 2 animals receiving 105.STCDso intracerebrally became 
paralyzed, and one of 3  given 104.STCD~0 showed lesions at all levels of the 
cord but gave no evidence of muscle weakness or other CNS signs. The 104.5- 
TCD60 intraspinally induced paralysis in 2 of 3 animals;  10a.STCDs0 failed to 
produce paralysis but produced lesions locally at the site of the injection and 
on the contralateral side of the lumbar cord in one of 3 animals. 
TABLE X 
Tests for Virulence on Type III KPa4 strain. Incidence of Lesions or Paralysis after Intraspinal 
and Intracerebral Inoculation 
Virus tested 
Leon KP3** (virus fed) 
Excreted by patient S-9[[ 
Excreted by patient S-40[[ 
Log of TCDso  inoculated 
Intraspinally 
I  6._~_5  5.5  I  4.5  3.5 
3/4~  2/3  2/4  1/4 
(3)§  (t)  (1)  (o) 
2/2  1/2 
(1)  (o) 
2/3  1/3 
(2)  (0) 
2.5 
0/4 
2/3 
(1) 
o/3 
IntraeerebrsU 
4.3 
0/11  0/4  0/4  0/4 
i/2  2/3  1/2  0/2 
(0)  (1)  (1) 
2/3  1/3  1/2  1/3 
(i)  (1)  0)  (o) 
3.3 
0/4 
* Tests carried out by Sabin (9, 31, 32). 
:~ Denominator, number tested; numerator number with lesions and~or paralysis. 
§ Number in parentheses indicates number paralyzed. 
ti When present, lesions  found in lumbar and cervical cord in all but two animals, in which 
only lumbar level involved. 
Although  in  both  instances  the  excreted virus  showed  some  increase  in 
virulence by the intracerebral test (see Table X), nevertheless it remained a 
relatively  attenuated  strain,  since  approximately  100,000  TCDs0  were  re- 
quired to produce paralysis in intercerebrally inoculated animals. 
Somewhat different results, however, were obtained when the excreted virus 
from the  same  two  infected individuals  was  tested  by the  "in  vitro  plaque 
virulence test" of Dulbecco and Vogt as given in reference 22 and as modified 
for use in bottles by Hsiung and Melnick (17, 23) in that the virus from one 
individual, S-40, behaved as a virulent strain. This test depends on the  differ- 
ence between virulent and attenuated  strains  in  rate of growth  and  size  of 
plaques  in  high  and  low  concentrations  of bicarbonate  ion:  the  attenuated 
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concentrations,  whereas  virulent  strains  produce  approximately equal  num- 
bers of plaques at both  low and  high  bicarbonate  concentrations.  The virus 
isolated from S-9,  13 days after virus feeding, behaved in the manner charac- 
teristic  for attenuated  strains,  while  that  isolated  from S-40,  some 6  weeks 
after virus feeding,  behaved in  the manner  characteristic  of virulent  strains. 
The following table lists the efficiency of plating virus as present in the second 
tissue  culture  passage from both  patients  and  in  addition  directly from the 
stool of one.  Efficiency of plating refers to  the  ratio of PFU per milliliter in 
bottles containing 0.075  gm.  per  cent  of NaHCO3  in  the  overlay, to that  in 
bottles containing 0.45 gm. per cent NaHCO3: 
S-9, 2nd TC passage  ......... 
S-40, stool ................. 
"  ,2nd TC passage ....... 
PFU/ml. 
NaHCOs concentration 
0.075 gin. per cent 
>10  ~ 
>50 
M5 X  l0  s 
0.45  gm.  per cent 
4.8 X  10" 
1.5X  10  ~ 
5  X  106 
Efl~cie~tcy  of  plating* 
<0.00003 
>0.33 
> 0.10 
* Plaque tests kindly performed by Dr.  G. D. Hsiung. All earlier stool specimens from 
S-40 which have been tested have yielded virus which behaved similarly; i.e.  in the pattern 
of virulent strains. 
DISCUSSION 
This trial confirms the observation that it is possible to reinfect individuals 
who posses homotypic antibodies acquired through  previous natural infection. 
Thus,  three of four whose natural  Type III antibody titer ranged from  8  to 
64 became reinfected. In addition,  one child  whose Type III antibodies were 
acquired by vaccination, also became infected.  This confirms similar, recently 
published findings  by Sabin  (13,  14),  and  the  clinical  and  field observations 
already quoted (1-3). Although four individuals in our trial were infected and 
excreted  virus,  there  was  no  indication  of any spread  of  the  agent  to  close 
contacts,  all  of whom were  adults,  either  those  with  antibodies,  or  the  one 
individual  who was antibody negative. 
The results in artificially infected humans follow a pattern similar to that observed 
in  chimpanzees in  this  laboratory  (24) and  by Howe, Bodian,  and  Morgan  (25). 
Chimpanzees are readily infected on first exposure to poliovirus.  On being challenged 
orally with a strain of which they had previously been carriers, homotypic immunity 
could be demonstrated in most animals, but in a small percentage (8 per cent) rein- 
fection occurred in our experiments. In contrast, challenge  with an heterotypic strain 
produced reinfection in 70 per cent of animals. 
In the earliest report of Koprowski et al.  (5) on the oral infection of human volun- 
teers with an attenuated Type II virus, three persons with naturally acquired Type II 
antibodies at levels of 1:94 to 1:900 were fed doses ranging from 10  s'l to 105"s MLDso. 174  ORAL  ADMINISTRATION O1  ~  ATTENUATED POLIOVIRUS 
Two of the three were found to be excreting virus on day 5 and day 23 respectively 
after feeding, but neither of these developed any increase in neutralizing antibodies 
following virus  excretion.  The third  individual neither excreted virus nor showed 
any change in antibody status. 
In  studies  reported by Sabin  (12),  all four adults  who had low level naturally 
acquired neutralizing antibodies prior to ingestion of large amounts of virus, excreted 
virus and all developed rises in titer; two others, fed smaller doses (104"~  TCD~0) failed 
to develop alimentary infection or antibody rise,  even though they possessed only 
traces of homotypic antibody before virus feeding. 
Our results are unlike Koprowski's but parallel those of Sabin  (12) in  that all 
individuals  in whom virus multiplication occurred showed an increase in neutralizing 
antibody fiter. In our trial, those fed the larger dose (107"5  TCDm) all became infected, 
whereas only one of two with natural antibodies fed the smaller dose (104'5  TCD~) did 
so. Furthermore, the one who resisted reinfection with the lower dosage had a lower 
prefeeding level  of homotypic antibody (1:16)  than the one who became infected 
(1:64), suggesting that the titer of antibody is not the only factor concerned in pre- 
venting reinfection (12-14). 
The amounts of virus excreted in the four infected subjects were similar,  ranging 
from 10  l's to 104.6 TCDm per gram of stool. There was a difference, however,  in the 
duration of excretion: the 3 with naturally acquired antibodies  passed  virus for a 
total of from 7 to 13 days, while the child whose antibodies had been acquired through 
vacckuation, continued to excrete the agent until some time between the 41st and 63rd 
postfeeding day. Thus in  this  single  observation, the  excretion of virus following 
infection in  a  child  with  Salk  vaccine-induced  antibodies continued for at least 6 
weeks, a duration comparable to that seen in natural primary infection (26), while 
those with similar levels of antibody, acquired naturally, excreted virus for a  brief 
period of 7 to  13 days only. Long duration of virus excretion  in infants following 
infection induced in  the presence of passive--maternally acquired--antibody has 
recently been described by Koprowski et al. (27). 
The absence of viremia in the experimental subjects, all of whom had homol- 
ogous antibody before being fed,  is  not surprising.  Neither Koprowski  (5, 6) 
nor Sabin (11-14) have detected vlremia in individuals fed laboratory attenu- 
ated strains of virus even though they had no nomotypic antibody at the time 
of feeding. In fact, on the basis of experience to date, failure to induce viremia 
might turn out to be an essential characteristic in any strain labeled "atten- 
uated". 
The antibody responses of the four infected individuals were variable and not 
related to dosage, duration of excretion, presence or absence of virus in  the 
throat. Of the three with naturally acquired prefeeding neutralizing antibody, 
all showed sharp and persistent (over 84 days) neutralizing antibody rises; the 
heterotypic responses were slighter and more transient in two (S-8 and S-21) 
and high and persistent in the other (S-9). The only person of these three who 
developed an appreciable CF response (S-8) already had CF antibodies at the 
time of virus feeding, whether from a  recent poliovirus infection, or infection HORST~rANN, PAUL, MELNICK, AND  DEUTSCH  175 
with an antigenically related agent, is not known. Of the other two individuals 
only one showed a transient CF response, the other none at all, although both 
had vigorous neutralizing antibody reactions. Whether minimal or absent CF 
response is a  characteristic pattern on reinfection cannot be determined until 
more subjects are studied. 
The child with formalinized vaccine-induced neutralizing antibodies had the 
smallest homotypic neutralizing antibody response, but was the only one with 
a  fourfold rise in CF antibodies, both homo- and heterotypic. 
It has been suggested that persons with previous antibody, whether naturally 
or artificially acquired, will respond to reinfection with a  more rapid rise in 
antibody than do those experiencing a primary infection (28). This was not the 
case in the four individuals studied in the present experiments: the neutraliz- 
ing and CF antibodies appeared at about 7 to 10 days, the same time interval 
at which they have appeared in primary experimental infections (5,  12). 
The results of tests for virulence on recovered virus (Tables VIII and IX) 
indicate that a  higher degree of neurotropism was  present in the virus being 
excreted than in the material ingested by the volunteers. The KP34 strain, when 
tested by Sabin et  al.  (9,  11,  12)  failed to produce paralysis in cynomologus 
monkeys on  intracerebral  injection,  even when  107.~ TCDs0  were  given; he 
found  that  none  of  28  monkeys  receiving  intracerebral  dosages  ranging 
from  101"2 to  10  ~-~  TCDs0  (4  animals  per  dilution)  developed  paralysis  or 
demonstrable CNS lesions. In contrast, the virus excreted by 2 of our patients, 
produced paralysis in both animals given a dosage of 105.8 TCDs0,  and in one 
instance, lesions in one of two animals given 104.8 TCD60. A likely explanation 
of this increased virulence is that the KP34 virus strain fed, represented a mix- 
ture of neurotropic and non-neurotropic particles, despite its "purification" by 
the terminal dilution method. This has recently been shown by Sabin (14) to be 
the case: when the strain was plated by the plaque method (29)  both neuro- 
tropic and non-neurotropic colonies were found. In terms of our experiment, the 
2nd tissue culture passage of the virus excreted apparently contained relatively 
more  neurotropic particles  than did the  ingested virus.  The  question  as  to 
whether passage in humans had resulted in the emergence of more neurotropic 
particles, or whether it was the two subsequent passages in tissue culture which 
had favored their appearance, cannot be answered as far as monkey virulence 
is concerned, since the titer of virus in the stools was too low to allow adequate 
direct test. 
The results of the  "in vitro plaque virulence test" agreed with the monkey 
virulence tests in the one instance, but was at variance with it in the other. It 
is not possible to assess the significance of this observation until more is known 
of the correlation of results by the two different methods. However, Hsiu~ag 
and Melnick have obtained data with other strains of poliovirus which gave a 
positive in vitro test for virulence (high efficiency of plating at low bicarbonate 176  ORAL  ADMINISTRATION  OF ATTENUATED  POLIOVIRUS 
concentration), but which failed to produce disease when 1000 to 100,000 PFU 
were inoculated intracerebrally into rh,sus monkeys (23). 
This observation on apparent increase in virulence raises the old question as 
to whether it is possible to demonstrate a change, i. e. an enhancement or degra- 
dation in the virulence of microorganisms, during the course of a single clinical 
infection. It would seem that future work on a large number of subjects might 
give valuable results relative to this point. 
SUMMARY 
Four of five individuals possessing homotypic antibody in titers of 8 to 64 
were infected on being fed Type III  (Leon KP-34) poliovirus attenuated by 
Sabin by passage through tissue culture. 
None of the infected subjects or controls showed any evidence  of illness which 
could be attributed to virus infection. 
There was  no evidence of spread of infection to  any of the control adult 
wardmates of the experimental subjects, although the two groups were in close 
contact: none of the controls excreted virus, none showed any antibody shift. 
One control who had no Type III antibodies at the start of the experiment was 
still antibody-negative on the 63rd day of the experiment. 
Three of the four individuals who became infected had naturally acquired- 
Type III antibodies; the other had antibodies induced by formalinized vaccine. 
Virus excretion in the stool was of short duration (7 to 13 days) in the three 
with natural antibodies, and lasted at least 6  weeks after feeding in the vac- 
cinated child. 
Virus in the throat was detected only in the two persons receiving the larger 
virus dose (107.5 TCDs0). In them it was present in small amounts between the 
2nd and 6th day after feeding. 
No virus was detected in the blood of any of the infected individuals. 
The antibody responses of the four infected individuals were variable. There 
was no clear correlation with virus dosage, amount of virus excretion in the 
stools, or presence of virusin the throat. Only the child whose neutralizing anti- 
bodies were "Salk" vaccine induced showed a marked CF response. 
The virus excreted by two of the individuals who became infected, as tested 
in  the 2nd  tissue  culture passage  by monkey inoculation, was  slightly more 
neurotropic than the virus which was ingested. Virus excreted by one of these 
individuals  behaved as  a  virulent strain  when  tested by the in  vitro  plaque 
virulence test, while that isolated from the other had the characteristics of an 
attenuated strain in this test. 
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